Skip to main content
GPCR
NASDAQ Life Sciences

Structure Therapeutics Q1 10-Q Reveals Strong Phase 2 Weight-Loss Data, $1.46B Liquidity

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$39.35
Mkt Cap
$2.893B
52W Low
$15.8
52W High
$94.9
52W Position info
149% above low
Off High info
59% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

GPCR has more than doubled off its 52-week low of $15.8.

Summary

Structure Therapeutics reported its Q1 2026 results, with a net loss of $75.97 million and EPS of ($0.35), aligning with prior analyst expectations. The 10-Q filing, however, delivered significant positive news regarding its clinical pipeline and financial strength. The company highlighted strong Phase 2 ACCESS/ACCESS II clinical trial results for its lead obesity drug, aleniglipron, demonstrating up to ~16% placebo-adjusted weight loss at 44 weeks, which supports a planned Phase 3 start in Q3 2026. Furthermore, Structure Therapeutics confirmed a robust financial position with $1.46 billion in liquidity, including a $100 million license fee, providing a substantial cash runway to fund operations and upcoming Phase 3 activities. This positive clinical progress and strong capital position are highly material for the company's long-term valuation, overshadowing the anticipated quarterly losses. Traders will closely monitor the initiation and progress of the pivotal Phase 3 trials.

At the time of this announcement, GPCR was trading at $39.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $15.80 to $94.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

GPCR - Latest Insights

GPCR
Nov 11, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $20.95
Real-time Price: $16.69 info
Change: -$4.26 (-20%) info
Market Cap: $1.151B info
GPCR
Nov 09, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $16.69 info
Change: -$4.72 (-22%) info
Market Cap: $1.151B info
GPCR
Nov 09, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $16.69 info
Change: -$4.72 (-22%) info
Market Cap: $1.151B info
GPCR
Sep 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $36.78
Real-time Price: $16.69 info
Change: -$20.09 (-55%) info
Market Cap: $1.151B info
GPCR
Sep 08, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.60
Real-time Price: $16.69 info
Change: -$30.91 (-65%) info
Market Cap: $1.151B info